75 related articles for article (PubMed ID: 20473854)
41. The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer.
Santegoets SJ; Welters MJP; Schrikkema DS; Freriks MR; Kok H; Weissbrich B; van den Branden A; Linnemann C; Schumacher TN; Adhikary S; Bendle G; van der Burg SH
Cancer Immunol Immunother; 2023 Jun; 72(6):1553-1565. PubMed ID: 36526910
[TBL] [Abstract][Full Text] [Related]
42. Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.
Chakravarthy A; Reddin I; Henderson S; Dong C; Kirkwood N; Jeyakumar M; Rodriguez DR; Martinez NG; McDermott J; Su X; Egawa N; Fjeldbo CS; Skingen VE; Lyng H; Halle MK; Krakstad C; Soleiman A; Sprung S; Lechner M; Ellis PJI; Wass M; Michaelis M; Fiegl H; Salvesen H; Thomas GJ; Doorbar J; Chester K; Feber A; Fenton TR
Nat Commun; 2022 Oct; 13(1):5818. PubMed ID: 36207323
[TBL] [Abstract][Full Text] [Related]
43. Interferon-γ and IL-5 associated cell-mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa.
Paaso A; Koskimaa HM; Welters MJP; Kero K; Rautava J; Syrjänen K; van der Burg SH; Syrjänen S
Clin Exp Dent Res; 2021 Oct; 7(5):903-913. PubMed ID: 33421352
[TBL] [Abstract][Full Text] [Related]
44. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
Zhang Y; Yu M; Jing Y; Cheng J; Zhang C; Cheng L; Lu H; Cai MC; Wu J; Wang W; Lou W; Qiu L; Tan L; Lu H; Yin X; Zhuang G; Di W
Br J Cancer; 2021 Jan; 124(2):414-424. PubMed ID: 33087896
[TBL] [Abstract][Full Text] [Related]
45. Human papilloma virus load and PD-1/PD-L1, CD8
Balermpas P; Martin D; Wieland U; Rave-Fränk M; Strebhardt K; Rödel C; Fokas E; Rödel F
Oncoimmunology; 2017; 6(3):e1288331. PubMed ID: 28405521
[TBL] [Abstract][Full Text] [Related]
46. The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization.
Koskimaa HM; Paaso A; Welters MJP; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1491-1503. PubMed ID: 28324192
[TBL] [Abstract][Full Text] [Related]
47. Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4
Muraro E; Merlo A; Martorelli D; Cangemi M; Dalla Santa S; Dolcetti R; Rosato A
Front Immunol; 2017; 8():197. PubMed ID: 28289418
[TBL] [Abstract][Full Text] [Related]
48. Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.
van Poelgeest MI; Visconti VV; Aghai Z; van Ham VJ; Heusinkveld M; Zandvliet ML; Valentijn AR; Goedemans R; van der Minne CE; Verdegaal EM; Trimbos JB; van der Burg SH; Welters MJ
Cancer Immunol Immunother; 2016 Dec; 65(12):1451-1463. PubMed ID: 27619514
[TBL] [Abstract][Full Text] [Related]
49. Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative.
Koskimaa HM; Paaso A; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 Nov; 13():370. PubMed ID: 26608420
[TBL] [Abstract][Full Text] [Related]
50. The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome.
Gorter A; Prins F; van Diepen M; Punt S; van der Burg SH
J Transl Med; 2015 Sep; 13():295. PubMed ID: 26357849
[TBL] [Abstract][Full Text] [Related]
51. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
[TBL] [Abstract][Full Text] [Related]
52. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
Santegoets SJ; Dijkgraaf EM; Battaglia A; Beckhove P; Britten CM; Gallimore A; Godkin A; Gouttefangeas C; de Gruijl TD; Koenen HJ; Scheffold A; Shevach EM; Staats J; Taskén K; Whiteside TL; Kroep JR; Welters MJ; van der Burg SH
Cancer Immunol Immunother; 2015 Oct; 64(10):1271-86. PubMed ID: 26122357
[TBL] [Abstract][Full Text] [Related]
53. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
54. Immunologic treatments for precancerous lesions and uterine cervical cancer.
Vici P; Mariani L; Pizzuti L; Sergi D; Di Lauro L; Vizza E; Tomao F; Tomao S; Cavallotti C; Paolini F; Venuti A
J Exp Clin Cancer Res; 2014 Mar; 33(1):29. PubMed ID: 24667138
[TBL] [Abstract][Full Text] [Related]
55. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.
Koskimaa HM; Paaso AE; Welters MJ; Grénman SE; Syrjänen KJ; van der Burg SH; Syrjänen SM
J Transl Med; 2014 Feb; 12():44. PubMed ID: 24524328
[TBL] [Abstract][Full Text] [Related]
56. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
van Poelgeest MI; Welters MJ; van Esch EM; Stynenbosch LF; Kerpershoek G; van Persijn van Meerten EL; van den Hende M; Löwik MJ; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Melief CJ; Kenter GG; van der Burg SH
J Transl Med; 2013 Apr; 11():88. PubMed ID: 23557172
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy of human papilloma virus induced disease.
van der Burg SH
Open Virol J; 2012; 6():257-63. PubMed ID: 23341861
[TBL] [Abstract][Full Text] [Related]
58. Therapy of human papillomavirus-related disease.
Stern PL; van der Burg SH; Hampson IN; Broker TR; Fiander A; Lacey CJ; Kitchener HC; Einstein MH
Vaccine; 2012 Nov; 30 Suppl 5(0 5):F71-82. PubMed ID: 23199967
[TBL] [Abstract][Full Text] [Related]
59. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens.
Keskin DB; Reinhold B; Lee SY; Zhang G; Lank S; O'Connor DH; Berkowitz RS; Brusic V; Kim SJ; Reinherz EL
Front Immunol; 2011; 2():75. PubMed ID: 22566864
[TBL] [Abstract][Full Text] [Related]
60. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
Kim KH; Greenfield WW; Cannon MJ; Coleman HN; Spencer HJ; Nakagawa M
Cancer Immunol Immunother; 2012 Jan; 61(1):63-70. PubMed ID: 21842207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
